Economic analysis of the Confronting COPD survey: Methodology

Respiratory Medicine

Volumn 97, Issue SUPPL. C, 2003, Pages

  Halpern, Michael T ^a   Musin, A ^b   Sondhi, S ^b  

^a EXPONENT INC   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Burden; Chronic obstructive pulmonary disease; COPD; Cross sectional study; Methodology; Questionaire; Resource utilization

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; THEOPHYLLINE;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROMOTION; HEALTH STATUS; HEALTH SURVEY; HUMAN; METHODOLOGY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PRODUCTIVITY; QUANTITATIVE ANALYSIS; SOCIETY; WORKPLACE;

EID: 0037372989     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(03)80021-5     Document Type: Article

References (35)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Executive Summary. NHLBI/WHO Workshop Report 2001.
2. World Health Organisation. World Health Statistics Annual 1995. Geneva:WHO, 1995.
3. Murray CJL, Lopez AD, eds. The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990, and projected to 2020. Cambridge, MA: Harvard University Press, 1996.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
5. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000; 117(Suppl 2): 1S-4S.
6. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. Chest 2000; 117: 1146-1161.
7. Ketalaars CA, Schlosser MA, Mostert R, et al. Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 39-43.
8. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease state and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072-1079.
9. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117(Suppl 2): 5S-9S.
10. Vermeire P. The burden of chronic obstructive pulmonary disease. Respir Med 2002; 96(Suppl C): S3-S10.
11. Jacobson L, Lindgren B, Löfdahl CG, Skoogh BE, Lindgren B. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000; 94: 247-255.
12. Rennard S, Decramer M, Calverley PM, et al. The impact of COPD in North America and Europe in 2000: The patient's perspective of the Confronting COPD International Survey. Eur Respir J 2002; 20: 799-805.
13. Decramer M, Pride NB, Soriano JB, et al. International differences of the burden of COPD. Chest 2003 (in press).
14. Pearson M. Raising the profile of chronic obstructive pulmonary disease with healthcare decision-makers. Respir Med 2000; 96(Suppl C): S1-S2.
15. Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999; 240: 1881-1887.
16. Wouters EFM. Economic analysis of the Confronting COPD survey: overview of results. Respir Med 2003; 97(Suppl C): S3-S14.
17. Chapman KR, Bourbeau J, Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C): S23-S31.
18. Piperno D, Huchon G, Pribil C, Boucot I, Smilowski T. The burden of COPD in France: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S33-S42.
19. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S43-S50.
20. Wouters EFM. The burden of COPD in the Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S51-S59.
21. Izquierdo JL. The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S61-S69.
22. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S71-S79.
23. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med 2003; 97(Suppl C); S81-S89.
24. International Telecommunications Union. World Telecommunications Indicators: 2000-2001. Geneva: International Telecommunications Union, 2001.
25. Toren J, Brisman J, Jarvholm B. Asthma and asthma-like symptoms in adults assessed by questionnaires. Chest 1993; 104: 600-608.
26. Galobardes B, Sunyer J, Anto JM, et al. Effect of the method of administration, mail or telephone, on the validity and reliability of a respiratory health questionnaire. J Clin Epidemiol 1998; 51: 875-881.
27. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
28. Heaney LG, McAllister D, MacMahon J. Cost minimisation analysis of provision of oxygen at home: are Drug Tariff guidelines cost-effective. BMJ 1999; 319: 19-23.
29. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor zorgverzekeringen, 2000.
30. Bestall JC, Paul EA, Garood R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6.
31. Siafakas NM, Vermeire P, Pride NB, et al. ERS-consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir Rev 1995; 8: 1398-1420.
32. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802-807.
33. Calverley PMA, Sondhi S. The burden of obstructive lung disease in the U.K. - COPD and asthma. Thorax 1998; 53(Suppl 4):A83, P237.
34. Division of Epidemiology. National Heart, Lung and Blood Institute 1996. http://www.nhlbi.nih.gov
35. Nowak D. Sozialmedizin, rehabilitation, begutachtung. In: Konietzko N (ed.). Bronchitis. München: Urban and Schwartzenberg 1995: 233-253.